ovarian neoplasm – Talk Bio

Actionable Insights Powered by AI

Rezatapopt Shows Early Promise in TP53 Y220C-Mutant Tumors in PYNNACLE Phase II Trial

2 weeks ago talkbio0Tagged Familial mitral valve prolapse, ORR, ovarian neoplasm, p53 reactivator, Phase 2 Clinical Trials, PYNNACLE trial, Rezatapopt, Solid Neoplasm, Targeted Therapy, TP53 gene, Y220C mutation

Rezatapopt; TP53 Y220C mutation; PYNNACLE trial; solid tumors; phase II clinical trial; ORR; ovarian cancer; p53 reactivator; targeted therapy; PMV Pharmaceuticals

Edison Oncology Presents Two Posters at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2 months ago talkbio0Tagged AACR-NCI-EORTC, ARID1A mutation, Clinical Trials, Edison Oncology, Molecular Targets, Orotecan, ovarian neoplasm, OXPHOS pathway, Phase 1 - 2a, VAL-413

Edison Oncology; 2025 AACR-NCI-EORTC; Molecular Targets; Cancer Therapeutics; VAL-413; Orotecan; EO3001; ARID1A mutation; ovarian cancer; Phase 1-2a clinical trial; OXPHOS pathway

Merck & Co. Announces Keytruda Achieves First Overall Survival Benefit in Resistant Ovarian Cancer

2 months ago talkbio0Tagged checkpoint inhibitor, Co., KEYNOTE-B96 trial, Keytruda, Merck, ovarian neoplasm, Overall Survival, PD-L1, pembrolizumab, platinum-resistant, Progression-Free Survival

Merck & Co.; Keytruda; pembrolizumab; ovarian cancer; platinum-resistant; overall survival; checkpoint inhibitor; KEYNOTE-B96 trial; progression-free survival; PD-L1

PMV Pharma’s p53 Drug Shows Effect in Ovarian Cancer, but Financial Challenges Loom

3 months ago talkbio0Tagged cash runway, Clinical Trials, Familial mitral valve prolapse, File (record), Frequency of Responses, Funding, ovarian neoplasm, TP53 gene, United States Food and Drug Administration

PMV Pharmaceuticals; rezatapopt; p53; ovarian cancer; clinical trial; response rate; FDA filing; funding; cash runway

GSK Reports Mixed Results for Jemperli/Zejula Combination in First-Line Ovarian Cancer Trial

12 months ago talkbio0Tagged Clinical Trials, first-line, Jemperli, mixed survival data, ovarian neoplasm, SmithKline Beecham, Zejula

GSK, Jemperli, Zejula, ovarian cancer, first-line treatment, mixed survival data, clinical trial results

GSK’s Zejula-Jemperli Combination Achieves Primary Endpoint in Ovarian Cancer Trial, Falls Short on Overall Survival

12 months ago talkbio0Tagged FIRST trial, Jemperli, ovarian neoplasm, Progression-Free Survival, SmithKline Beecham, Survival, Zejula

GSK, Zejula, Jemperli, ovarian cancer, FIRST trial, progression-free survival, overall survival

Keytruda and Lynparza Combination Shows Partial Success in Ovarian Cancer Trial

1 year ago talkbio0Tagged Clinical Trials, Keytruda, Lynparza, ovarian neoplasm, Progression-Free Survival, Survival

Keytruda, Lynparza, ovarian cancer, clinical trial, progression-free survival, overall survival

GSK’s Zejula Fails to Meet Overall Survival Goal in First-Line Ovarian Cancer, Combination Therapy Disappoints

1 year ago talkbio0Tagged Combined Modality Therapy, first-line, Maintenance, niraparib, ovarian neoplasm, Overall Survival, Restricted, second-line, SmithKline Beecham, United States Food and Drug Administration, Zejula

Zejula, niraparib, GSK, ovarian cancer, first-line treatment, overall survival, combination therapy, FDA, restriction, second-line maintenance

AbbVie Achieves Early Return on Investment with $10 Billion Immunogen Acquisition Following Phase II Ovarian Cancer Success

2 years ago talkbio0Tagged AbbVie, Antibody-Drug Conjugates, Antigens, Elahere, ovarian neoplasm, Phase 2 Clinical Trials, Return on Investment, ROI

AbbVie, Immunogen, Ovarian Cancer, Phase II Trial, Return on Investment (ROI), Antibody-Drug Conjugate (ADC), Elahere

AbbVie’s $10.1 Billion ImmunoGen Acquisition Bears Fruit with Elahere’s Mid-Stage Success in Ovarian Cancer Treatment

2 years ago talkbio0Tagged AbbVie, Acquisition (action), Antibody-Drug Conjugates, Antigens, Clinical Trials, Elahere, Neoplasms, ovarian neoplasm

AbbVie, ImmunoGen, Elahere, Ovarian Cancer, Antibody-Drug Conjugate (ADC), Clinical Trial, Acquisition, Oncology